Goldman Sachs analyst Kevin Kumar maintained a Buy rating on WalkMe (WKME – Research Report) today and set a price target of $18.00. The company’s shares closed last Tuesday at $8.93.
According to TipRanks.com, Kumar is ranked #5819 out of 7897 analysts.
WalkMe has an analyst consensus of Strong Buy, with a price target consensus of $19.60, representing an 89.4% upside. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on WalkMe’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $53.26 million and GAAP net loss of $26.48 million. In comparison, last year the company earned revenue of $38.91 million and had a GAAP net loss of $17.8 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
WalkMe Ltd is the defining solution enabling organizations to better realize the value of software investments. It is a cloud-based digital adoption platform, users employees and customers of organizations can navigate websites, SaaS applications, and mobile apps through a digital, GPS-like experience to accomplish any task from simple, online transactions, to complex cross-application software processes, to fully autonomous experiences that require no manual clicks or entries.
Read More on WKME:
- Edgewise Therapeutics (EWTX) Gets a Hold Rating from Goldman Sachs
- Vor Biopharma (VOR) Receives a Hold from Goldman Sachs
- Goldman Sachs Thinks Roivant Sciences’ Stock is Going to Recover
- Goldman Sachs Thinks Codiak BioSciences’ Stock is Going to Recover
- Relay Therapeutics (RLAY) Gets a Buy Rating from Goldman Sachs
